The spinal cord stimulation device for chronic pain market was valued at US$ 799.87 million in 2022 and is expected to reach US$ 1.41 billion by 2030; it is estimated to register at a CAGR of 7.4% from 2022 to 2030.
Spinal cord stimulation devices are highly adopted in rehabilitation centers. A treatment method based on these devices supports patients physically and psychologically to maximize their neurological recovery and general health in a short time. The Walk Again Center based in Berlin is one such example of a rehabilitation center to treat neurological conditions.
This rehab center employs both medicine and technology to treat SCIs. It uses innovative medical procedures, including structural and neural neuroplasticity, where doctors provide therapy to patients suffering from brain damage. Therefore, advanced rehab centers and specialized centers provide growth opportunities to the Europe spinal cord stimulation devices for chronic pain market.
for instance, in Italy, spinal cord treatments in hospitals are fully covered under insurance through the Italian National Health System (NHS). Therefore, there is high awareness of effective treatments available for SCIs among the Italian population. Therefore, the availability of proper health coverage provisions for SCI signifies a high demand for spinal cord stimulation devices among hospitals and specialty centers in Italy.
Rehabilitation and Specialized Centers Providing Effective Treatment for Spinal Cord Injuries Fuels Spinal Cord Stimulation Device for Chronic Pain Market
According to a report by the NIH, specialized centers of care for SCI were first established in England with an objective to improve the care and neurological recovery of patients. SCI tertiary care centers are developed to improve clinical outcomes and neurological recovery among patients suffering from acute SCIs. Additionally, the Spinal Cord Injury Center at Heidelberg University Hospital in Germany is the only academic center dedicated to the treatment and research of SCIs. The staff at Heidelberg University Hospital, including ~145 staff members, provides treatment to ~1,500 patients suffering from acute or chronic spinal cord injuries annually, among which 1,000 receive outpatient care.Spinal cord stimulation devices are highly adopted in rehabilitation centers. A treatment method based on these devices supports patients physically and psychologically to maximize their neurological recovery and general health in a short time. The Walk Again Center based in Berlin is one such example of a rehabilitation center to treat neurological conditions.
This rehab center employs both medicine and technology to treat SCIs. It uses innovative medical procedures, including structural and neural neuroplasticity, where doctors provide therapy to patients suffering from brain damage. Therefore, advanced rehab centers and specialized centers provide growth opportunities to the Europe spinal cord stimulation devices for chronic pain market.
Europe Spinal Cord Stimulation Device for Chronic Pain Market Overview
Europe spinal cord stimulation device for chronic pain market by region, is segmented as Germany, France, Italy, Spain, United Kingdom, Switzerland, Netherlands, Sweden, and Rest of Europe. The rising healthcare claims and associated costs, increasing administrative transactions, and spinal cord stimulation device for chronic pain platform in supply chain tracking are among the prominent factors propelling the market growth.for instance, in Italy, spinal cord treatments in hospitals are fully covered under insurance through the Italian National Health System (NHS). Therefore, there is high awareness of effective treatments available for SCIs among the Italian population. Therefore, the availability of proper health coverage provisions for SCI signifies a high demand for spinal cord stimulation devices among hospitals and specialty centers in Italy.
Europe Spinal Cord Stimulation Device for Chronic Pain Market Segmentation
The spinal cord stimulation device for chronic pain market is segmented based on product type, application, end user, and country.- Based on product type, the spinal cord stimulation device for chronic pain market is bifurcated into rechargeable and non-rechargeable. The rechargeable segment held a larger share in 2022.
- In terms of application, the spinal cord stimulation device for chronic pain market is segmented into failed back syndrome, complex regional pain syndrome, degenerative disk disease, and others. The complex regional pain syndrome segment held the largest share in 2022.
- By end user, the spinal cord stimulation device for chronic pain market is segmented into hospitals, ambulatory surgery centers (ASCS), and others. The hospitals segment held the largest share in 2022.
- Based on country, the spinal cord stimulation device for chronic pain market is categorized into Germany, France, the UK, Spain, Italy, Switzerland, Sweden, Poland, Belgium, Slovakia, Czech Republic, Greece, Ireland, the Netherland, and the Rest of Europe. Germany dominated the spinal cord stimulation device for chronic pain market in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Spinal Cord Stimulation Device for Chronic Pain Market - Market Landscape
5. Europe Spinal Cord Stimulation Device for Chronic Pain Market
6. Spinal Cord Stimulation Device for Chronic Pain Market - Europe Analysis
7. Europe Spinal Cord Stimulation Device for Chronic Pain Market - Revenue and Forecast to 2030 - by Product Type
8. Europe Spinal Cord Stimulation Device for Chronic Pain Market Revenue and Forecasts to 2030- by Application
9. Europe Spinal Cord Stimulation Device for Chronic Pain Market Revenue and Forecasts to 2030- by End User
10. Europe Spinal Cord Stimulation Device for Chronic Pain Market - Revenue and Forecast to 2030 -Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Boston Scientific Corp
- Abbott Laboratories
- Medtronic Plc
- Biotronik SE & Co KG
- Nevro Corp
- Cirtec Medical Corp
- Synapse Biomedical Inc
